1. Fenofibrate "might" reduce risk of cardiovascular events. Fenofibrate was
    Cynthia S. Brown Cynthia S. Brown United States says:
    December 29, 2016 at 2:36 PM

    Fenofibrate "might" reduce risk of cardiovascular events.  Fenofibrate was given the okay by the FDA for use in diabetic patients, and is what is now referred to as an "off-label" drug when used in conjunction with treating heart disease and physicians need to make sure that they are explaining this to their diabetic patients.  Just call me a little skeptical when it comes to pharmaceutical companies pushing their off-label drugs through physicians...

    Reply
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback